Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cytokine receptor common subunit beta, also known as CSF2RB or CD131, is a critical cell surface receptor component involved in immune regulation and hematopoiesis. It serves as the shared signaling subunit for the receptors of three type I cytokines: granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and interleukin-5 (IL-5). Upon ligand binding to the receptor complex, CSF2RB initiates intracellular signaling cascades—primarily through JAK1 activation leading to downstream JAK–STAT pathway signaling—which regulate immune responses and control production/differentiation of hematopoietic progenitor cells into various blood lineages. Alterations in βc-mediated pathways have been implicated in various diseases including chronic inflammation and malignancies.
Modulation of JAK-STAT pathway signaling through GM-CSF, IL-3, and IL-5 receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytokine receptor common subunit beta (CSF2RB).